About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Preventing Transplant Drugs Before Conception Benefits Fetus

by Bidita Debnath on October 25, 2013 at 11:51 PM
Font : A-A+

 Preventing Transplant Drugs Before Conception Benefits Fetus

Fetal exposure to mycophenolic acid products (MPA)-which are drugs taken by transplant recipients to prevent rejection-may increase the risk of birth defects and spontaneous abortions, suggests research.

Results of this study will be presented at ASN Kidney Week 2013 November 5¬-10 at the Georgia World Congress Center in Atlanta, GA.

Advertisement

To investigate these potential links, Serban Constantinescu, MD, PhD (Temple University School of Medicine) and his colleagues analyzed data from the National Transplantation Pregnancy Registry (NTPR), comparing 163 female kidney transplant recipients who discontinued MPA prior to conception with 114 recipients who conceived while taking MPA.

In recipients who discontinued MPA, there were more live births (79% vs. 43%), a lower incidence of miscarriages (19% vs. 52%), and a lower incidence of birth defects (6% vs. 14%). Kidney problems during and after pregnancy were similar in the two groups of transplant recipients.
Advertisement

"The results of this study generate multiple questions. Continued close collaboration among specialists will help to better identify potential pregnancy risks in kidney transplant recipients, particularly as new immunosuppressive agents are developed," said Dr. Constantinescu. "Individual physicians and transplant centers are encouraged to report all pregnancy exposures in transplant recipients to the National Transplantation Pregnancy Registry, which was designed specifically to assess the safety of pregnancy in solid organ transplant recipients."

Study: "Pregnancy Outcomes in Kidney Recipients Who Discontinued Mycophenolic Acid Products Prior to Conception." (Abstract 3136)

Michael J. Moritz is a consultant for Highmark Blue Shield and receives research funding from Novartis and Bristol-Meyers-Squibb. The authors report receiving research funding for this study from Commercial Support Novartis Pharmaceuticals Corp., Astellas Pharma US, Inc., Pfizer Inc., and Bristol-Myers Squibb Co.

ASN Kidney Week 2013, the largest nephrology meeting of its kind, will provide a forum for 14,000 professionals to discuss the latest findings in renal research and engage in educational sessions related to advances in the care of patients with kidney and related disorders. Kidney Week 2013 will take place November 5 - 10, 2013 in Atlanta, GA.

The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

Founded in 1966, and with more than 14,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.

Source: Newswise
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Health Benefits of Sea Buckthorn
Contraceptive Pills in Polycystic Ovary Syndrome (PCOS) Curtail Type 2 Diabetes Risk
Mushroom May Help Cut Down the Odds of Developing Depression
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Artificial Insemination Pregnancy and Antenatal Care Drugs Banned in India 

Recommended Reading
Future Transplant Therapies Could be Aided By Stem Cell Breakthrough
Scientists have developed a new method for creating stem cells for the human liver and pancreas, ......
Organ Transplants may Up the Risk of Kidney Disease in Children
A new study has suggested a strong link between organ transplants of solid organs in children, and ....
Chances Of Relapse Reduced By Alcoholism Treatment Before, After Liver Transplantation
Liver transplant recipients who receive substance abuse treatment before and after transplantation ....
Suicide Genes Promise New Hope for Life-Saving Transplants
For the first time doctors have given kids' life-saving transplants of immune cells, engineered to ....
Artificial Insemination
Artificial Insemination is a medical procedure usually used to treat infertility. In this procedure,...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Drugs Banned in India
Several drugs are either banned or withdrawn after introduction in the market....
Pregnancy and Antenatal Care
What is Antenatal care and its importance during pregnancy for mother and baby, with details on the ...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use